Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor
Open accessThe DOI matches its Crossref record; 189 of the 191 references it cites were found in a registry or an index.
Abstract
The discovery of robust antidepressant actions exerted by the N -methyl-D-aspartate receptor (NMDAR) antagonist ( R,S )-ketamine has been a crucial breakthrough in mood disorder research. ( R,S )-ketamine is a racemic mixture of equal amounts of ( R )-ketamine (arketamine) and ( S )-ketamine (esketamine). In 2019, an esketamine nasal spray from Johnson & Johnson was approved in the United States of America and Europe for treatment-resistant depression. However, an increasing number of preclinical studies show that arketamine has greater potency and longer-lasting antidepressant-like effects than esketamine in rodents, despite the lower binding affinity of arketamine for the NMDAR. In clinical trials, non-ketamine NMDAR-related compounds did not exhibit ketamine-like robust antidepressant actions in patients with depression, despite these compounds showing antidepressant-like effects in rodents. Thus, the rodent data do not necessarily translate to humans due to the complexity of human psychiatric disorders. Collectively, the available studies indicate that it is unlikely that NMDAR plays a major role in the antidepressant action of ( R,S )-ketamine and its enantiomers, although the precise molecular mechanisms underlying antidepressant actions of ( R,S )-ketamine and its enantiomers remain unclear. In this paper, we review recent findings on the molecular mechanisms underlying the antidepressant actions of ( R,S )-ketamine and its potent enantiomer arketamine. Furthermore, we discuss the possible role of the brain–gut–microbiota axis and brain–spleen axis in stress-related psychiatric disorders and in the antidepressant-like action of arketamine. Finally, we discuss the potential of arketamine as a treatment for cognitive impairment in psychiatric disorders, Parkinson’s disease, osteoporosis, inflammatory bowel diseases, and stroke.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Major metabolisms of ketamine enantiomers. Arketamine is metabolized to (R)-norketamine that is metabolized to (2 R,6 R)-hydroxynorketamine (HNK). In addition, arketamine is also metabolized to (2 R,6 R)-hydroxyketamine that is metabolized (2 R,6 R)-HNK. Esketamine is metabolized to (S)-norketamine that is metabolized to (2 S,6 S)-HNK. In addition, esketamine is metabolized to (2 S,6 S)-hydroxyketamine that is metabolized to (2 S,6 S)-HNK. Ki values for NMDAR are presented in parenthesis [46, 49].](https://figures.cochat.ai/paper-figures/1778f3582562456ca2a0625d030a3c53/molecular-mechanisms-underlying-the-antidepressant-actions-of-arketamine-beyond-figure-1.jpg)

![Fig. 3 Role of brain–gut–microbiota axis and brain–spleen axis in the stress-related psychiatric disorders and beneficial effects by arketamine. Repeated stress caused gut microbiota dysbiosis and an increase in spleen size and weight, resulting in abnormalities in immune system. Stress-induced neuroinflammation might be mediated by the brain–gut–microbiota axis and the brain–spleen axis through the vagus nerve. Interestingly, arketamine could ameliorate the abnormalities of gut microbiota, abnormal functions of the spleen, and depressive symptoms in patients with stress-related disorders. A slight modification from the previous report [44]. Some materials of the figure have been designed using resources from Freepik.com.](https://figures.cochat.ai/paper-figures/bff9831e6cfa46d889185d75fe02f1ac/molecular-mechanisms-underlying-the-antidepressant-actions-of-arketamine-beyond-figure-3.jpg)
![Fig. 4 Potential of arketamine for cognitive impairments in psychiatric disorders and other diseases. Preclinical findings suggest that arketamine would be a new therapeutic drug for cognitive impairments in psychiatric disorders, neurodegenerative disorders such as Parkinson’s disease, osteoporosis, IBDs (ulcerative colitis and Crohn’s disease), and stroke. Importantly, patients with these diseases have depressive symptoms as comorbidity. IBD is a risk factor for PD [180]. Some materials of the figure have been designed using resources from Freepik.com.](https://figures.cochat.ai/paper-figures/f9e491a9d8694ebc82290e961a5b326b/molecular-mechanisms-underlying-the-antidepressant-actions-of-arketamine-beyond-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For now, the therapeutic primacy of NMDAR inhibition and resultant AMPAR potentiation appears a temporary frontrunner in the dynamic glutamatergic antidepressant landscape [75,76].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [75]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Lim, S. S., Abbafati, C., Abbas, K. M., Abbasi, M., Abbasifard, M., Abbasi-Kangevari, M., Abbastabar, H., Abd-Allah, F., Abdelalim, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30925-9 · Cited by 19,358
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Cryan, J. F., O'Riordan, K. J., Cowan, C. S. M., Sandhu, K. V., Bastiaanssen, T. F. S., Boehme, M., Codagnone, M. G., Cussotto, S., Fulling, C., Golubeva, A. V., et al. (2019) · Physiological Reviews · doi:10.1152/physrev.00018.2018 · Cited by 5,286
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 1×
“[19] demonstrated that a single intravenous infusion of (R,S)-ketamine (0.”
BackgroundA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
The role of short-chain fatty acids in microbiota–gut–brain communication
Dalile, B., Van Oudenhove, L., Vervliet, B., & Verbeke, K. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0157-3 · Cited by 3,357
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Nestler, E. J., Barrot, M., DiLeone, R. J., Eisch, A. J., Gold, S. J., & Monteggia, L. M. (2002) · Neuron · doi:10.1016/s0896-6273(02)00653-0 · Cited by 3,217
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904 · cited 1×
“It is well accepted that NMDAR antagonists such as ketamine and PCP cause detrimental side effects, including psychosis and dissociation in humans in proportion to their potency at the NMDAR [97], and the difference in NMDAR potency between the two ketamine enantiomers may explain the divergence in their dissociative…”
BackgroundmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Research works printed but not linked: 1
- Press release: Perception Neuroscience’s PCN-101 (R-ketamine) demonstrates tolerability in phase 1 single ascending dose study. https://www.perceptionns.com/news.
Cited by
Brain–gut–microbiota axis in depression: A historical overview and future directions
Chang, L., Wei, Y., & Hashimoto, K. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.02.004 · Cited by 377
“depression despite various side effects, delayed clinical onset, and high non-response rates (Galecki et al., 2018; Hoyer, 2020; Wei et al., 2021).”
InfluentialSelf-citationCheng, J., Hu, H., Ju, Y., Liu, J., Wang, M., Liu, B., & Zhang, Y. (2024) · General Psychiatry · doi:10.1136/gpsych-2023-101374 · Cited by 196
“177 Previous research also revealed alterations in the gut microbiota during ketamine treatment.”
BackgroundMicroglial ERK-NRBP1-CREB-BDNF Signaling in Sustained Antidepressant Actions of (R)-Ketamine
Yao, W., Cao, Q., Luo, S., He, L., Yang, C., Chen, J., Qi, Q., Hashimoto, K., & Zhang, J.-C. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01377-7 · Cited by 216
“Further study using these mice with depression-like phenotypes is needed [24].”
BackgroundSelf-citationQiu, D., Wang, X.-M., Yang, J.-J., Chen, S., Yue, C.-B., Hashimoto, K., & Yang, J.-J. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.44514 · Cited by 192
“The esketamine group had a longer median (IQR) laryngeal mask removal time (14 [8-20] vs 10 [8-14] minutes; P = .”
BackgroundSelf-citationGut Microbiota in Anxiety and Depression: Unveiling the Relationships and Management Options
Kumar, A., Pramanik, J., Goyal, N., Chauhan, D., Sivamaruthi, B. S., Prajapati, B. G., & Chaiyasut, C. (2023) · Pharmaceuticals · doi:10.3390/ph16040565 · Cited by 154
“These results confirm that the brain–gut– microbiota axis influences stress resiliency and vulnerability [123,127].”
Result
Metadata
- Authors
- Wei, Y., Chang, L., & Hashimoto, K.
- Affiliations
- Chiba University (JP)
- Corresponding author
- Hashimoto, Kenji
- Venue
- Molecular Psychiatry
- Published
- 2021-05-07
- Volume
- 27
- Issue
- 1
- Pages
- 559-573
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- PMC
- PMC8960399
- OpenAlex
- W3158143766
- Cited by
- 248
- References
- 191
- Citations by year
- 2026: 23 · 2025: 51 · 2024: 58 · 2023: 43 · 2022: 55 · 2021: 18
- FWCI
- 5.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Molecular Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Japan Agency for Medical Research and Development (JP20dm0107119)
- National Natural Science Foundation of China (31701009)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- esketamine, antidepressant mechanism, NMDA receptor, treatment-resistant depression, brain-gut-microbiota axis, stress-related psychiatric disorders, cognitive impairment, Parkinson's disease, osteoporosis, inflammatory bowel disease, stroke
- MeSH terms
- Antidepressive Agents, Depression, Humans, Ketamine, Receptors, N-Methyl-D-Aspartate, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor. https://app.cochat.ai/papers/10.1038/s41380-021-01121-1
- The paper
- Wei, Y., Chang, L., & Hashimoto, K. (2022). Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor. Molecular Psychiatry. https://doi.org/10.1038/s41380-021-01121-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.